Robert Orlowski, Deputy Chair of Lymphoma/Myeloma, Vice Chair of MM Research, and Florence Maude Thomas Cancer Research Professor at the University of Texas MD Anderson Cancer Center, shared a post on X:
“Myeloma Paper of the Day:
SEMA4A expression is hi where BCMA density is low; its deletion limits myeloma cell growth, migration, tissue infiltration, and osteoclast formation; CAR T cells show superior efficacy vs. BCMA CAR T in pre-clinical models.”
Title: Developing SEMA4A-directed CAR T cells to overcome low BCMA antigen density in multiple myeloma
Authors: Francesco Di Meo, Francesca Albano, Annamaria Cesarano, Yunfei Wang, Brandon Kale, Kenneth Shain, Ariosto Silva, Noriyoshi Kurihara, Hirofumi Tenshin, David Jellyman, Xiaofei Song, Sasan Ghaffari, Hector Mesa, Ben Creelan, Ciara Freeman, Xiaohong Zhao, Mark B. Meads, Paulo C. Rodriguez, Silvia Marino, Frederick Locke, Patrick Hwu, David Roodman, Jorge Mansilla-Soto, and Fabiana Perna
You can read the Full Article in Cancer Cell.
You can find more posts featuring Robert Orlowski on OncoDaily.
